Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow Abstract #L02 💊Phase 3, randomized, placebo-controlled study 💉Biologic naive patients ✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi) 📍benefits sustained to week 52 🛑No new safety signals